Skip to main content

Dr Jack Broadfoot

MChem MBBCh MRCP

Education and training

  • MChem (Hons) Chemistry with industrial experience, University of Manchester, 2004
  • MBBCh (Hons) Medicine, Cardiff University, 2009
  • MRCP UK (London), 2014
  • Postgraduate certificate in oncology, Institute of Cancer Research, Royal Marsden, 2018
  • Certificate of completion of training in medical oncology, Wessex Deanery, 2022

Experience

Dr Broadfoot started his oncology training as a clinical fellow at Guy’s and St Thomas’ Cancer Centre in London from 2015. He first joined the Trust in 2016 as a specialty registrar in medical oncology, working here at Southampton as well as other regional hospitals including Portsmouth, Bournemouth and Salisbury. He completed a two year research fellowship in the Clinical Trials Unit at Southampton, before his appointment as a consultant medical oncologist here in 2023.

Dr Broadfoot specialises in the care of patients with urological malignancies, including prostate, kidney, bladder and testicular cancer. He is also the regional lead for patients with metastatic penile cancer.

Research

  • Nathan P, Wheater M, Sacco J, Broadfoot J, et al. National Uveal Melanoma Guidelines. https://melanomafocus.org/for-professionals/rare-melanoma-guidelines-and-consultations/uveal-melanoma-guidelines/
  • Whone A, Luz M, Boca M, Wooley M, Mooney L, Dharia S, Broadfoot J, et al. Randomised trial of glial cell line-derived neurotrophic factor (GDNF) administered via intermittent intraputamenal convection-enhanced delivery (CED) in Parkinson’s Disease. Brain. 2019;142(3):512-525.
  • Whone AL, Boca M, Luz M, Woolley M, Mooney L, Dharia S, Broadfoot J, et al. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease. J Parkinsons Dis. 2019;9(2):301-313.
  • Broadfoot J and Johnson PWM. Response-adapted therapy in Hodgkin Lymphoma. Hematol Oncol. 2017; 35 Suppl 1:33-36.
  • Broadfoot JR, Archer HA, Love S, et al. Paraneoplastic tumefactive demyelination with underlying combined germ cell cancer. Pract Neurol. 2015;15(6):451-5.

Contact

You can contact Dr Broadfoot via the medical oncology secretaries by emailing MedicalOncologyPPCs@uhs.nhs.uk